A 5-Question Quiz on Pediatric Hematologic Cancers

June 1, 2017
Debra Hughes
Debra Hughes

In the first blinatumomab trial, what percentage of pediatric ALL patients achieved a complete remission? What is the effect of vitamin D and calcium supplementation on bone mineral density in the pediatric ALL population? Test your knowledge in our latest quiz.

In the first blinatumomab trial, what percentage of pediatric acute lymphoblastic leukemia (ALL) patients achieved a complete remission? And what is the effect of vitamin D and calcium supplementation on bone mineral density in the pediatric ALL population? Test your knowledge in our latest quiz.

Question 1

Answer

D. cMpl

Granulocyte macrophase progenitor predominance in CML progenitors at diagnosis may also predict poor outcome, according to a recent study. The authors “recommend flow cytometric analysis of bone marrow in the early phase of treatment, as it is a convenient tool that may predict treatment response and guide CML management.”

Question 2

Answer

A. 15- to 21-year-olds

Patients in this age group were significantly less likely to use CCC/COG sites than children (P < .001), according to the study. Among 22- to 39-year-olds, those less likely to use CCC/COG sites were 30- to 39-year olds, had public insurance or were uninsured, or were African American or Hispanic.

Question 3

Answer

A. BMD scores decreased in the first 2 years, then increased

“Vitamin D and calcium supplementation in pediatric ALL patients during intensive chemotherapy may not prevent bone mineral loss, ” according to the study. These results were similar to those described in other studies.

Question 4

Answer

B. Sticker reminders on treatment road maps

“Our efforts are now being directed at improving screening and interventions prior to day 8,” the investigators of the study noted. The goal, they wrote, is to “standardize blood glucose screening and hyperglycemia intervention algorithms to decrease both the time-to-initiation for insulin and readmission rate for symptomatic hyperglycemia” for patients at their institution.

Question 5

Answer

B. 39%

Among the 70 patients who received the recommended dose of blinatumomab, 27 patients (39%) achieved complete remission within the first 2 cycles. Of those, 14 (52%) had minimal residual disease response, the authors of the study noted.